CALGB-80802: Sorafenib With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer (H-26756)
This study compares the effects of standard of care therapy (sorafenib) with or without the addition of doxorubicin to learn which treatment is better. Patients must have locally advanced or metastatic hepatocellular carcinoma (HCC), and not have received any prior therapy for metastatic disease, or liver/bone marrow transplants. Patients are randomized to 1 of 2 treatments: sorafenib + doxorubicin; or sorafenib alone.
For more information: http://www.clinicaltrials.gov/ct2/show/NCT01015833